Medical - Care Facilities
Compare Stocks
2 / 10Stock Comparison
CCM vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
CCM vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Care Facilities | Biotechnology |
| Market Cap | $748K | $1712.35T |
| Revenue (TTM) | $366M | $0.00 |
| Net Income (TTM) | $-163M | $-168M |
| Gross Margin | -11.4% | — |
| Operating Margin | -131.0% | — |
| Forward P/E | 1.4x | — |
| Total Debt | $3.93B | $22M |
| Cash & Equiv. | $216M | $194M |
CCM vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Concord Medical Ser… (CCM) | 100 | 41.3 | -58.7% |
| DBV Technologies S.… (DBVT) | 100 | 40.7 | -59.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CCM vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
CCM carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 0 yrs, beta 0.53
- Rev growth -28.6%, EPS growth -3.6%, 3Y rev CAGR -7.5%
- Lower volatility, beta 0.53, current ratio 0.46x
DBVT is the clearest fit if your priority is long-term compounding.
- -87.0% 10Y total return vs CCM's -88.8%
- 0.3% margin vs CCM's -44.6%
- +110.4% vs CCM's -28.4%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | -28.6% revenue growth vs DBVT's -100.0% | |
| Quality / Margins | 0.3% margin vs CCM's -44.6% | |
| Stability / Safety | Beta 0.53 vs DBVT's 1.26 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +110.4% vs CCM's -28.4% | |
| Efficiency (ROA) | -2.4% ROA vs DBVT's -89.0% |
CCM vs DBVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
CCM vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
CCM and DBVT operate at a comparable scale, with $366M and $0 in trailing revenue.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $366M | $0 |
| EBITDAEarnings before interest/tax | -$359M | -$112M |
| Net IncomeAfter-tax profit | -$163M | -$168M |
| Free Cash FlowCash after capex | $0 | -$151M |
| Gross MarginGross profit ÷ Revenue | -11.4% | — |
| Operating MarginEBIT ÷ Revenue | -131.0% | — |
| Net MarginNet income ÷ Revenue | -44.6% | — |
| FCF MarginFCF ÷ Revenue | -2.1% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -8.3% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +84.0% | +91.5% |
Valuation Metrics
Evenly matched — CCM and DBVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $748,461 | $1712.35T |
| Enterprise ValueMkt cap + debt − cash | $547M | $1712.35T |
| Trailing P/EPrice ÷ TTM EPS | -0.02x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | 1.37x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.01x | — |
| Price / BookPrice ÷ Book value/share | 0.00x | 0.66x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
Evenly matched — CCM and DBVT each lead in 4 of 8 comparable metrics.
Profitability & Efficiency
CCM delivers a -9.8% return on equity — every $100 of shareholder capital generates $-10 in annual profit, vs $-130 for DBVT. DBVT carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to CCM's 2.43x. On the Piotroski fundamental quality scale (0–9), DBVT scores 4/9 vs CCM's 3/9, reflecting mixed financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -9.8% | -130.2% |
| ROA (TTM)Return on assets | -2.4% | -89.0% |
| ROICReturn on invested capital | -7.7% | — |
| ROCEReturn on capital employed | -12.2% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | 2.43x | 0.13x |
| Net DebtTotal debt minus cash | $3.7B | -$172M |
| Cash & Equiv.Liquid assets | $216M | $194M |
| Total DebtShort + long-term debt | $3.9B | $22M |
| Interest CoverageEBIT ÷ Interest expense | -2.40x | -189.82x |
Total Returns (Dividends Reinvested)
DBVT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DBVT five years ago would be worth $3,090 today (with dividends reinvested), compared to $1,512 for CCM. Over the past 12 months, DBVT leads with a +110.4% total return vs CCM's -28.4%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs CCM's -27.2% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +20.4% | +4.9% |
| 1-Year ReturnPast 12 months | -28.4% | +110.4% |
| 3-Year ReturnCumulative with dividends | -61.4% | +19.7% |
| 5-Year ReturnCumulative with dividends | -84.9% | -69.1% |
| 10-Year ReturnCumulative with dividends | -88.8% | -87.0% |
| CAGR (3Y)Annualised 3-year return | -27.2% | +6.2% |
Risk & Volatility
Evenly matched — CCM and DBVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
CCM is the less volatile stock with a 0.53 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DBVT currently trades 76.3% from its 52-week high vs CCM's 47.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.51x | 1.26x |
| 52-Week HighHighest price in past year | $10.77 | $26.18 |
| 52-Week LowLowest price in past year | $3.18 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +47.7% | +76.3% |
| RSI (14)Momentum oscillator 0–100 | 67.5 | 48.1 |
| Avg Volume (50D)Average daily shares traded | 11K | 252K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates CCM as "Buy" and DBVT as "Buy".
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | — | $46.33 |
| # AnalystsCovering analysts | 2 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 0 | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
DBVT leads in 2 of 6 categories — strongest in Income & Cash Flow and Total Returns. 3 categories are tied.
CCM vs DBVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is CCM or DBVT a better buy right now?
Analysts rate Concord Medical Services Holdings Limited (CCM) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison.
The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CCM or DBVT?
Over the past 5 years, DBV Technologies S.
A. (DBVT) delivered a total return of -69. 1%, compared to -84. 9% for Concord Medical Services Holdings Limited (CCM). Over 10 years, the gap is even starker: DBVT returned -87. 1% versus CCM's -87. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CCM or DBVT?
By beta (market sensitivity over 5 years), Concord Medical Services Holdings Limited (CCM) is the lower-risk stock at 0.
51β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 149% more volatile than CCM relative to the S&P 500. On balance sheet safety, DBV Technologies S. A. (DBVT) carries a lower debt/equity ratio of 13% versus 2% for Concord Medical Services Holdings Limited — giving it more financial flexibility in a downturn.
04Which is growing faster — CCM or DBVT?
On earnings-per-share growth, the picture is similar: Concord Medical Services Holdings Limited grew EPS -3.
6% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — CCM or DBVT?
DBV Technologies S.
A. (DBVT) is the more profitable company, earning 0. 0% net margin versus -80. 3% for Concord Medical Services Holdings Limited — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DBVT leads at 0. 0% versus -138. 6% for CCM. At the gross margin level — before operating expenses — DBVT leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — CCM or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is CCM or DBVT better for a retirement portfolio?
For long-horizon retirement investors, Concord Medical Services Holdings Limited (CCM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
51)). Both have compounded well over 10 years (CCM: -87. 5%, DBVT: -87. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between CCM and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.